An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions

Ecotoxicology and Environmental Safety

Volumn 72, Issue 6, 2009, Pages 1625-1634

  Straub, Jürg Oliver ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Ecotoxicological effects; Environmental fate; Oseltamivir; Pandemic; Predicted environmental concentrations; Risk assessment; Tamiflu

Indexed keywords

OSELTAMIVIR; SURFACE WATER;

DOSE-RESPONSE RELATIONSHIP; DRUG; ECOTOXICOLOGY; ENVIRONMENTAL FATE; ENVIRONMENTAL RISK; RISK ASSESSMENT; SEWAGE; SURFACE WATER;

ALGA; ARTICLE; CATCHMENT; CONTROLLED STUDY; DAPHNIA; DRUG USE; ECOTOXICITY; ENVIRONMENTAL HEALTH; FISH; HEALTH HAZARD; INFLUENZA; NONHUMAN; PANDEMIC; PREDICTION; RISK ASSESSMENT; SEWAGE; TREATMENT DURATION; UNITED KINGDOM; WESTERN EUROPE;

ALGAE; ANIMALS; ANTIVIRAL AGENTS; DAPHNIA; DISEASE OUTBREAKS; DRAINAGE, SANITARY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FISHES; FRESH WATER; GEOLOGIC SEDIMENTS; HUMANS; INFLUENZA, HUMAN; KINETICS; OSELTAMIVIR; RISK ASSESSMENT; SEASONS; SEWAGE; TOXICITY TESTS; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL;

COLORADO BASIN [NORTH AMERICA]; ENGLAND; EURASIA; EUROPE; LEA RIVER; NORTH AMERICA; UNITED KINGDOM; WESTERN EUROPE;

ALGAE; DAPHNIA;

EID: 67349123515     PISSN: 01476513     EISSN: 10902414     Source Type: Journal    
DOI: 10.1016/j.ecoenv.2008.09.011     Document Type: Article

References (38)

1. Accinelli, C., Barra Caracciolo, A., Grenni, P., Saccà, M.L., 2007a. Degradation of the antiviral drug oseltamivir (Tamiflu) in surface water. Poster, SETAC Europe 17th Annual Meeting, Porto (P), May 20-24, 2007.
2. Accinelli C., Barra Caracciolo A., and Grenni P. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int. J. Environ. Anal. Chem. 87 (2007) 579-587
3. Anderson P.D., D'Aco V.J., Shanahan P., Chapra S.C., Buzby M.E., Cunningham V.L., Duplessie B.M., Hayes E.P., Mastrocco F.J., Parke N.J., Rader J.C., Samuelian J.H., and Schwab B.W. Screening analysis of human pharmaceutical compounds in US surface waters. Environ. Sci. Technol. 38 (2004) 838-849
4. Bartels P., and von Tümpling W. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci. Total Environ. 405 (2008) 215-225
5. Cafarella, M.A., 2008a. Oseltamivir (ester+carboxylate) mixture 20:80 (w/w): alga, growth inhibition test with Pseudokirchneriella subcapitata (syn. Selenastrum capricornutum) under static conditions. Springborn Smithers Europe, Horn, Switzerland; Study no. 1114.000.430, on behalf of F. Hoffmann-La Roche Ltd, Basle, unpublished.
6. Cafarella, M.A., 2008b. Oseltamivir (ester+carboxylate) mixture 20:80 (w/w): chronic reproduction test with daphnids (Daphnia magna) under semi-static conditions. Springborn Smithers Europe, Horn, Switzerland; Study no. 1114.000.230, on behalf of F. Hoffmann-La Roche Ltd, Basle, unpublished.
7. Cafarella, M.A., 2008c. Oseltamivir (ester+carboxylate) mixture 20:80 (w/w): fish early life-stage toxicity test with zebrafish (Danio rerio syn. Brachydanio rerio) under flow-through conditions. Springborn Smithers Europe, Horn, Switzerland; Study no. 1114.000.122, on behalf of F. Hoffmann-La Roche Ltd, Basle, unpublished.
8. EC. Annex to commission directive 92/69/EEC of 31 July 1992. Methods for the determination of ecotoxicity. C.1 acute toxicity for fish. Off. J. Eur. Commun. L 383A (1992) 1-235
9. EMEA, 2006. Note for guidance on environmental risk assessment of medicinal products for human use. CPMP/SWP/4447/00, EMEA, London, UK. 〈http://www.emea.eu.int/pdfs/human/swp/444700en.pdf/〉, accessed February 2008.
10. EPISuite, 2007. EPISuite v3.20. US environmental protection agency and syracuse research center; model downloadable at 〈http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm〉, accessed March 2008.
11. Eurostat, 2008. Population data for January 2007. 〈http://epp.eurostat.ec.europa.eu/〉, accessed February 2008.
12. EUSES, 2004. European union system for the evaluation of substances. ECB, Ispra, Italy. 〈http://ecb.jrc.it/〉, accessed February 2008.
13. F. Hoffmann-La Roche Ltd. Safety Data Sheet for Oseltamivir Phosphate (2007), F. Hoffmann-La Roche Ltd, Basel, Switzerland. 04.01.2007 〈http://www.roche.com/home/sustainability/sus_env/sus_sds_search.htm〉 accessed March 2008
14. Fick J., Lindberg R.H., Tysklind M., Haemig P.D., Waldenström J., Wallensten A., and Olsen B. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS ONE 2 10 (2007) e986 10.1371/journal.pone.0000986 accessed March 2008
15. Häner, A., 2006. Oseltamivir phosphate SK, inherent biodegradability-evaluation of the aerobic biodegradability in an aqueous medium: modified MITI test (II). BMG Engineering, Schlieren, Switzerland; BMG report 1405/b-05 on behalf of F. Hoffmann-La Roche Ltd, unpublished.
16. Joss A., Carballa M., Kreuzinger N., Siegrist H., and Zabczynski S. Wastewater treatment. In: Ternes T.A., and Joss A. (Eds). Human Pharmaceuticals, Hormones and Fragrances: The Challenge of Micropollutants in Urban Water Management (2006), IWA Publishing, London 243-292
17. Kelleher, S.L., Dempsey, M.J., 2007. The effect of oseltamivir carboxylate on nitrification of wastewater by bioparticles from a pilot-scale expanded bed bioreactor. Poster, Tamiflu and the Environment Workshop, Oxford, UK, October 3, 2008.
18. In: Kümmerer K. (Ed). Pharmaceuticals in the Environment. second ed (2004), Springer, Berlin
19. Lienert J., Güdel K., and Escher B.I. Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes. Environ. Sci. Technol. 41 (2007) 4471-4478. Supporting Information at 〈http://pubs.acs.org/subscribe/journals/esthag/suppinfo/es0627693/es0627693si20070405_093915.pdf〉 accessed March 2008
20. McLaughlin, S.P., 2008. Determination of the inherent biodegradability of oseltamivir by the porous pot test, based on OECD303A guideline and the OPPTS method 835.3220. Springborn Smithers Laboratories, Wareham, MA, USA; Study no. 1698.6104, on behalf of F. Hoffmann-La Roche Ltd, Basle, unpublished.
21. OECD. OECD Guidelines for the Testing of Chemicals, Test No. 210: Fish, Early-Life Stage Toxicity Test; Adopted 17 July 1992 (1992), OECD, Paris
22. OECD. OECD Guidelines for the Testing of Chemicals, Test No. 211: Daphnia Magna Reproduction Test; Adopted 21 September 1998 (1998), OECD, Paris
23. OECD. OECD Guideline for the Testing of Chemicals, Test No. 303: Simulation Test-Aerobic Sewage Treatment: 303 A: Activated Sludge Units-303 B: Biofilms; Adopted 22 January 2001 (2001), OECD, Paris
24. OECD. OECD Guidelines for the Testing of Chemicals, Test No. 308: Aerobic and Anaerobic Transformation in Aquatic Sediment Systems; Adopted 24 April 2002 (2002), OECD, Paris
25. OECD. OECD Guidelines for the Testing of Chemicals, Test No. 309: Aerobic Mineralisation in Surface Water-Simulation Biodegradation Test; Adopted 13 April 2004 (2004), OECD, Paris
26. OECD. OECD Guidelines for the Testing of Chemicals, Test No. 201: Alga, Growth Inhibition Test; Adopted 22 March 2006 (2006), OECD, Paris
27. POSEIDON, 2006. Assessment of technologies for the removal of pharmaceuticals and personal care products in sewage and drinking water facilities to improve the indirect potable water reuse. EU EVK1-CT-2000-00047; Project coordinator T. Ternes. Final report available at: 〈http://poseidon.bafg.de/servlet/is/2884/〉, accessed March 2008.
28. Schünemann H.J., Hill S.R., Kakad M., Bellamy R., Uyeki T.M., Hayden F.G., Yazdanpanah Y., Beigel J., Chothpitayasunondh T., Del Mar C., Farrar J., Tinh Hien T., Özbay B., Sogaya N., Fukuda K., Shindo N., Stockman L., Vist G.E., Croisier A., Nagjdaliyev A., Roth C., Thomsan G., Zucker H., Oxman A.D., and for the WHO Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid advice guidelines for pharmaceutical management of sporadic human infection with avian influenza (H5N1) virus. Lancet Infect. Dis. 7 (2007) 21-31
29. SciFinder, 2008. American Chemical Society, SciFinder database online (subscription database).
30. Singer A.C., Nunn M.A., Gould E.A., and Johnson A.C. Potential risks associated with the proposed widespread use of Tamiflu. Environ. Health Persp. 115 (2007) 102-106
31. ® use under pandemic conditions-report from an interdisciplinary workshop. Environ. Health Persp., in press, doi:10.1289/ehp.11310.
32. Singer A.C., Johnson A.C., Anderson P.D., and Snyder S.A. Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado river. Environ. Health Persp. 116 (2008) A285-A286
33. SPARC On-Line Calculator, 2008. University of Georgia, Atlanta, GA, USA. 〈http://ibmLc2.chem.uga.edu/sparc/〉, accessed February 2008.
34. TGD. Technical Guidance Document for Risk Assessment (2003), ECB, Ispra, Italy. 〈http://ecb.jrc.it/〉 accessed February 2008
35. UniProt Knowledgebase online, 2008. UniProt/SwissProt/TrEMBLE entry for EC 3.2.1.18. 〈http://www.expasy.org/cgi-bin/nicezyme.pl?3.2.1.18〉, accessed August 2008.
36. van der Kolk, J., 2008a. Oseltamivir (ester+carboxylate) mixture 20:80 (w/w): aerobic transformation in aquatic sediments systems, OECD 308. Springborn Smithers Europe, Horn, Switzerland; Study no. 1114.000.750, on behalf of F. Hoffmann-La Roche Ltd, Basle, unpublished.
37. van der Kolk, J., 2008b. Oseltamivir (ester+carboxylate) mixture 20:80 (w/w): aerobic mineralisation in surface water-simulation biodegradation test, OECD 309. Springborn Smithers Europe, Horn, Switzerland; Study no. 1114.000.752, on behalf of F. Hoffmann-La Roche Ltd, Basle, unpublished.
38. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Disc. 6 (2007) 967-974